Medibank share price lifts on cyberattack ransom update

Medibank shares were placed in a trading halt for two days at the company's request on 13 October following news that customer medical data may have been hacked.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The Medibank share price is in the green this morning
  • The ASX 200 insurer was hit by a massive cyber breech on 12 October
  • Medibank said all its customers may have been impacted and it will not be paying the cybercriminal any ransom demands

The Medibank Private Ltd (ASX: MPL) share price is up 1.06% in early trade following an update from the S&P/ASX 200 Index (ASX: XJO) health insurer on the October data breach.

Medibank shares were placed in a trading halt for two days at the company's request on 13 October after news broke that customer medical data may have been hacked.

The initial fears proved founded, and the company again requested a trading halt later in October. When it resumed trading on 26 October, the Medibank share price closed down 18.1% on the day after the insurer revealed "significant amounts" of medical-related data from all of its customers may have been compromised.

Here's what the company reported today.

A woman looks in anticipation at her laptop, watching eagerly.

Image source: Getty Images

What's the latest response to the Medibank hack?

The Medibank share price is in the green after the company reiterated that it was taking "decisive action" related to the October cybercrime to protect its customers.

CEO David Koczkar also offered another "unreserved apology" to the impacted customers, saying the company understands the stress the data breach is causing them.

Medibank also reported it would not make any ransom payments to the criminal behind the hack.

Commenting on the company's decision not to pay the ransom, Koczkar said:

Based on the extensive advice we have received from cybercrime experts, we believe there is only a limited chance paying a ransom would ensure the return of our customers' data and prevent it from being published.

In fact, paying could have the opposite effect and encourage the criminal to directly extort our customers, and there is a strong chance that paying puts more people in harm's way by making Australia a bigger target.

At this stage of the investigation, Medibank believes the hacker accessed the name, date of birth, address, phone number and email address of roughly 9.7 million current and former customers and some of their authorised representatives.

"We will continue to support all people who have been impacted by this crime through our Cyber Response Support Program," Koczkar said. "This includes mental health and wellbeing support, identity protection and financial hardship measures."

The Medibank share price may also be getting some reprieve after the insurer said it had not detected any additional "suspicious activity" in its systems since the 12 October breach. It is continuing to work closely with the Australian Cyber Security Centre and the Australian Federal Police on the matter.

Medibank advised all former and current customers to remain vigilant with any online communications and transactions.

How has the Medibank share price tracked in 2022?

The Medibank share price was in the green for the calendar year until the fallout from the cyber-attack saw investors hitting the sell button. As of this morning, Medibank shares are down 18% in 2022, compared to a 9% loss posted by the ASX 200.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Scientists in white coats look disappointed.
Healthcare Shares

$5,000 invested in CSL shares 12 months ago is now worth…

Are the biotech company's shares worth holding onto?

Read more »

Happy healthcare workers in a lab.
Healthcare Shares

Clarity Pharmaceuticals shares are up 12% today. Here's what's driving the move

Today's announcement moves Clarity a step closer towards commercialisation.

Read more »

A medical specialist holds a red heart connected via technology and artificial intelligence.
Healthcare Shares

Which ASX biotech's shares are rocketing higher on big US news?

This company has more than doubled in value over the past three months.

Read more »

A man with a wry smile on his face is shown close up behind ascending piles of coins as he places another coin on top of the tallest stack representing rising dividends
Healthcare Shares

Here's the dividend forecast out to 2030 for CSL shares

Can healthy dividends continue from CSL?

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Forget CSL shares, this ASX healthcare stock could double in value

Brokers see significantly more upside ahead for Pro Medicus.

Read more »

Lab worker puts hands in the air and dances around.
Healthcare Shares

CSL shares look primed to take off — Here's why

Business remains robust and brokers see ASX stock soaring up to 100%.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

ASX 300 healthcare stock outperforming today on 'strategic' leadership news

The ASX healthcare stock announced the outcome of its CEO recruitment drive this morning.

Read more »

Cropped shot of a young female scientist working on her computer in the laboratory.
Healthcare Shares

Could Telix shares be a millionaire-maker stock?

Telix looks a compelling growth story, with brokers eyeing more than 150% upside.

Read more »